AUTO3

AUTO3 is a bicistronic chimeric antigen receptor (CAR) T-cell therapy developed for the treatment of B-cell malignancies such as acute lymphoblastic leukemia (ALL) and diffuse large B cell lymphoma (DLBCL). It is an autologous cell therapy product that co-expresses two humanized second-generation CARs targeting CD19 and CD22 antigens on B cells. The dual targeting approach aims to minimize relapse due to single antigen loss—a common resistance mechanism in current single-targeted CAR-T therapies. Developed by Autolus in collaboration with University College London, AUTO3 has demonstrated high efficacy and a favorable safety profile in early clinical trials for pediatric ALL and adult DLBCL. The product is manufactured using a bicistronic γ-retroviral vector to transduce patient-derived T cells with both anti-CD19 and anti-CD22 receptors[1][2][6][8].

Other names

CD19/CD22-targeted chimeric antigen receptor engineered T cellCD19/CD22 CAR-T